AKTS FY 2024 Earnings — Aktis Oncology, Inc. Revenue & Financial Results | Market Cap Arena

AKTSAktis Oncology, Inc.

$1B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

$1M100.0% margin

Operating Income

-$52M-3500.3% margin

Net Income

-$44M-2957.6% margin

EPS (Diluted)

$0.00

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$326M

Total Liabilities

$414M

Stockholders' Equity

-$88M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	$1M	$0	—
Operating Income	-$52M	-$35M	-49.6%
Net Income	-$44M	-$29M	-53.6%